Compare Organon & Co. Common Stock (OGN) vs Riot Platforms Inc (RIOT) Price & Performance

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

RIOT trades at $16.67, up 1.21% today, while showing bearish technical signals with 13 of 13 moving averages indicating sell signals. The company reported significant losses with a net income margin of -196.28% in 2026 and has missed earnings expectations for three consecutive quarters. However, analyst sentiment remains overwhelmingly positive with 94.74% buy ratings and a $31.64 consensus price target, reflecting optimism about the company's strategic shift toward data center operations and AI power capacity.

RIOT faces substantial fundamental challenges with persistent losses and negative cash flow, but the company's pivot to data center landlord strategy with $9.8 billion in contracted lease revenue through 2048 provides long-term revenue visibility. The stock offers significant upside potential if management can execute the business transition successfully, though investors must weigh the high valuation multiples against ongoing profitability concerns and execution risks in the competitive AI infrastructure market.